Effect of a Diagnostic Strategy Using an Elevated and Age-Adjusted D-Dimer Threshold on Thromboembolic Events in Emergency Department Patients With Suspected Pulmonary Embolism: A Randomized Clinical Trial.
Adult
Age Factors
Aged
Aged, 80 and over
Anticoagulants
/ therapeutic use
Cause of Death
Confidence Intervals
Cross-Over Studies
Emergency Service, Hospital
Female
Fibrin Fibrinogen Degradation Products
/ analysis
France
Hospitalization
/ statistics & numerical data
Humans
Length of Stay
Male
Middle Aged
Patient Readmission
/ statistics & numerical data
Prospective Studies
Pulmonary Embolism
/ blood
Reproducibility of Results
Spain
Venous Thromboembolism
/ blood
Young Adult
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
07 12 2021
07 12 2021
Historique:
entrez:
7
12
2021
pubmed:
8
12
2021
medline:
17
12
2021
Statut:
ppublish
Résumé
Uncontrolled studies suggest that pulmonary embolism (PE) can be safely ruled out using the YEARS rule, a diagnostic strategy that uses varying D-dimer thresholds. To prospectively validate the safety of a strategy that combines the YEARS rule with the pulmonary embolism rule-out criteria (PERC) rule and an age-adjusted D-dimer threshold. A cluster-randomized, crossover, noninferiority trial in 18 emergency departments (EDs) in France and Spain. Patients (N = 1414) who had a low clinical risk of PE not excluded by the PERC rule or a subjective clinical intermediate risk of PE were included from October 2019 to June 2020, and followed up until October 2020. Each center was randomized for the sequence of intervention periods. In the intervention period (726 patients), PE was excluded without chest imaging in patients with no YEARS criteria and a D-dimer level less than 1000 ng/mL and in patients with 1 or more YEARS criteria and a D-dimer level less than the age-adjusted threshold (500 ng/mL if age <50 years or age in years × 10 in patients ≥50 years). In the control period (688 patients), PE was excluded without chest imaging if the D-dimer level was less than the age-adjusted threshold. The primary end point was venous thromboembolism (VTE) at 3 months. The noninferiority margin was set at 1.35%. There were 8 secondary end points, including chest imaging, ED length of stay, hospital admission, nonindicated anticoagulation treatment, all-cause death, and all-cause readmission at 3 months. Of the 1414 included patients (mean age, 55 years; 58% female), 1217 (86%) were analyzed in the per-protocol analysis. PE was diagnosed in the ED in 100 patients (7.1%). At 3 months, VTE was diagnosed in 1 patient in the intervention group (0.15% [95% CI, 0.0% to 0.86%]) vs 5 patients in the control group (0.80% [95% CI, 0.26% to 1.86%]) (adjusted difference, -0.64% [1-sided 97.5% CI, -∞ to 0.21%], within the noninferiority margin). Of the 6 analyzed secondary end points, only 2 showed a statistically significant difference in the intervention group compared with the control group: chest imaging (30.4% vs 40.0%; adjusted difference, -8.7% [95% CI, -13.8% to -3.5%]) and ED median length of stay (6 hours [IQR, 4 to 8 hours] vs 6 hours [IQR, 5 to 9 hours]; adjusted difference, -1.6 hours [95% CI, -2.3 to -0.9]). Among ED patients with suspected PE, the use of the YEARS rule combined with the age-adjusted D-dimer threshold in PERC-positive patients, compared with a conventional diagnostic strategy, did not result in an inferior rate of thromboembolic events. ClinicalTrials.gov Identifier: NCT04032769.
Identifiants
pubmed: 34874418
pii: 2786829
doi: 10.1001/jama.2021.20750
pmc: PMC8652602
doi:
Substances chimiques
Anticoagulants
0
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
Banques de données
ClinicalTrials.gov
['NCT04032769']
Types de publication
Equivalence Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2141-2149Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
J Thromb Haemost. 2018 Apr;16(4):725-733
pubmed: 29431911
PLoS One. 2017 Jan 13;12(1):e0169268
pubmed: 28085911
Trials. 2020 Jun 3;21(1):458
pubmed: 32493383
Biometrics. 2004 Dec;60(4):919-25
pubmed: 15606412
JAMA. 2018 Feb 13;319(6):559-566
pubmed: 29450523
J Thromb Haemost. 2017 May;15(5):1040-1043
pubmed: 28296048
N Engl J Med. 2019 Nov 28;381(22):2125-2134
pubmed: 31774957
Lancet Haematol. 2017 Dec;4(12):e615-e621
pubmed: 29150390
JAMA Intern Med. 2018 Jun 1;178(6):812-819
pubmed: 29710111
Arch Intern Med. 2011 May 9;171(9):831-7
pubmed: 21555660
JAMA. 2006 Mar 8;295(10):1152-60
pubmed: 16522836
Lancet. 2017 Jul 15;390(10091):289-297
pubmed: 28549662
Eur J Emerg Med. 2019 Dec;26(6):458-461
pubmed: 31609876
Lancet. 2008 Apr 19;371(9621):1343-52
pubmed: 18424324
Clin Appl Thromb Hemost. 2012 Jan-Feb;18(1):20-6
pubmed: 21949040
Ann Emerg Med. 2013 Aug;62(2):117-124.e2
pubmed: 23433653
Eur J Emerg Med. 2021 Jun 1;28(3):165-166
pubmed: 33899776
JAMA. 2014 Mar 19;311(11):1117-24
pubmed: 24643601
J Thromb Haemost. 2020 Jun;18(6):1495-1500
pubmed: 32496023
Acad Emerg Med. 2018 Jul;25(7):828-835
pubmed: 29498138
Radiology. 2012 Feb;262(2):468-74
pubmed: 22187633
Thromb J. 2013 Jul 06;11(1):13
pubmed: 23829521
Crit Care Med. 2020 May;48(5):704-708
pubmed: 32079894
JAMA. 2020 Nov 17;324(19):1948-1956
pubmed: 33201202
Eur Respir J. 2019 Oct 9;54(3):
pubmed: 31473594
J Thromb Haemost. 2008 May;6(5):772-80
pubmed: 18318689
N Engl J Med. 2017 Oct 5;377(14):1357-1367
pubmed: 28976859
J Thromb Haemost. 2021 Jul;19(7):1832-1833
pubmed: 34176222